Actualités

Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.

By selecting high-quality stocks with above-average yields, the iShares Core High Dividend ETF generates sustainable income.

AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.

AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.

Companies in The News Are: APGE, ABBV, DLR, META, SNDK

European Commission Expands Skyrizi Label to Younger PatientsAbbVie (NYSE:ABBV) has received approval from the European Commission to use Skyrizi (risankizumab) in children and adolescents aged six years and older with moderate-to-severe plaque psoriasis who are eligible for systemic treatment. The authorization broadens the medicine’s reach within Europe and provides a new treatment option for younger patients living with the chronic inflammatory skin condition.

The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.

Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next? The Apogee setup is the template buyers are chasing: late-stage clinical data, a meaningful addressable market, ... 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

With a 5-Year Average Dividend Growth Rate of 6.33%, AbbVie Inc. (NYSE:ABBV) is included among the Top 11 Dividend Kings to Buy for Safe Dividend Growth. On June 22, Wells Fargo maintained an Overweight rating on AbbVie Inc. (NYSE:ABBV). It also set a $260 price target on the shares. The firm said AbbVie’s reported bid […]

An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline.

The gains showed increasing investor interest in companies benefiting from rising demand for AI infrastructure, large-scale chip manufacturing projects, and acquisitions.

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 10 Stocks Paying Off Big Time. Apogee Therapeutics soared to a fresh all-time high on Monday, as investors gobbled up shares following announcements that it is set to be acquired by pharmaceutical giant AbbVie Inc. at a 49 percent premium. In a joint statement on the same […]

The company is already renowned by many as a giant in the segment.

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

(Updates with index/price moves and political news from the first paragraph.) US equity indexes t

Yahoo Finance Senior Reporter Brooke DiPalma joins Josh Lipton in highlighting the day's biggest stories and stock moves, including AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE) and Coca-Cola's (KO) latest legal showdown with the IRS in US appeals court.

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.9% and

The $135.11 per share cash offer for Apogee carries a 49% premium

(Updates with latest market prices and developments.) US benchmark equity indexes were mixed intr

Nexentis Technologies (NXTS) said Monday its subsidiary, MitoCareX Bio, has entered into an engageme

(Updates with index/price moves and political/company news from the first paragraph.) US equity i

AbbVie (NYSE:ABBV) has agreed to acquire Apogee Therapeutics in a cash deal valued at US$10.9b. The transaction focuses on expanding AbbVie's immunology and respiratory disease pipeline with several clinical-stage candidates. The deal is described as AbbVie's largest acquisition in more than five years and includes a premium to Apogee's recent trading levels. AbbVie is a large biopharmaceutical company with a long-standing focus on immunology, oncology, neuroscience, and other specialty...

The Nasdaq Composite and S&P 500 were down, while the Dow Jones Industrial Average was up in late-mo

By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the last patient and visit in a 26-week study of PRO-203 in treatment-refractory lupus nephritis patients, […] The post Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing appeared first on ExecEdge.

The multi-billion-dollar bid could further cement AbbVie’s leading position in the immunology space as competition heats up.

On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn't need to conduct additional studies of the drug. - SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO.

While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.

AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.

Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma. Under...